VDPHL01 for Hair Loss: What the New Oral Minoxidil Does Differently
Published by AmpleLab Research
Our earlier article on oral minoxidil covered the current shift toward oral prescribing, and made a point of noting that the tablets being prescribed are immediate-release, a formulation originally developed for blood pressure in the 1970s, used off-label at doses arrived at informally by individual clinicians over the past decade. VDPHL01, developed by a New Haven biotech called Veradermics (NYSE: MANE), is a direct response to that gap: a purpose-built, extended-release oral minoxidil tablet, taken through formal FDA trials specifically for pattern hair loss, rather than borrowed from a different field of medicine.
This article covers what the extended-release formulation is actually designed to do differently, what the trial data published so far genuinely shows (a large, randomised, placebo-controlled male dataset, and a much smaller, open-label female dataset that means something different), and how VDPHL01's "first in decades" positioning compares to the similar claim Breezula is making, covered in our separate article on that drug.
What the Formulation Is Actually Designed to Do
VDPHL01 is minoxidil, the same active molecule already covered in depth in our main minoxidil article, and the same sulfotransferase-dependent activation pathway applies. What's different is the delivery mechanism: Veradermics describes a proprietary gel matrix designed to release minoxidil slowly and steadily, rather than the sharp spike and decline in blood concentration typical of an immediate-release tablet.
Veradermics' rationale is that the peak blood concentration (Cmax) associated with immediate-release dosing contributes to the systemic effects that can limit oral minoxidil, particularly at higher doses. An extended-release formulation aims to flatten that peak while keeping blood concentration above whatever threshold is needed to actually stimulate follicles, for a longer sustained period. If it works as intended, that's a genuinely different risk-benefit shape from immediate-release oral minoxidil, not just a repackaging of the same drug.
Whether the extended-release approach delivers on that rationale in practice is exactly what the trial data is meant to establish, so it's worth treating "designed to avoid the peak" as the design intent rather than an already-proven outcome, and looking at what the actual trials found next.
Study '302': The Large Male Dataset
This is currently the strongest evidence behind VDPHL01: a large, randomised, double-blind, placebo-controlled trial, the kind of design that can provide strong evidence for a causal treatment effect rather than simply an association.
519 men with mild-to-moderate pattern hair loss were randomised to VDPHL01 8.5mg once daily, 8.5mg twice daily, or placebo. At Month 6, mean non-vellus target-area hair count increased by 30.3 hairs/cm² (once daily) and 33.0 hairs/cm² (twice daily), versus 7.3 hairs/cm² for placebo (both p<0.0001). On patient-reported outcomes, 48.4% (once daily) and 62.9% (twice daily) reported "improved" or "much improved" hair coverage, versus 13.4% on placebo (both p<0.0001). Statistically significant separation from placebo was seen as early as Month 2. Adverse event rates were similar to placebo overall, with no treatment-related serious adverse events and no cardiac adverse events of special interest reported. This is topline, company-reported data, not yet a peer-reviewed publication with full methodology and safety tables, so treat it as a strong first look rather than the final word.
Two things worth noting about these numbers specifically. First, they're reported as absolute hair-count changes rather than relative percentages against placebo, which is a more directly interpretable figure than the kind of relative-improvement framing that can obscure the underlying magnitude. Second, the twice-daily dose also produced numerically larger improvements across the reported endpoints, although a formal statistical comparison between the two doses has not been published.
Study '207': The Female Data, and Why It's a Different Kind of Evidence
Female pattern hair loss data followed in July 2026, and it's genuinely encouraging, but it needs to be read differently from Study '302' because the trial design is different in ways that matter.
Study '207' was a small, open-label Phase 2 trial: 28 women with mild-to-moderate pattern hair loss received VDPHL01 4.5mg once or twice daily for 6 months, with no placebo arm and no blinding. At Month 6, mean hair count increased by 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily); 88.9% and 90.0% respectively reported "improved" or "much improved" hair coverage. No treatment-related serious adverse events or cardiac events of special interest were reported. These are encouraging numbers, but an open-label design without a comparator arm can't separate genuine drug effect from expectation effects or natural fluctuation over six months, which is why a larger controlled trial is needed to establish efficacy for an approval decision.
Veradermics itself describes Study '207' as proof-of-concept for the registration-directed trial, Study '306', a placebo-controlled Phase 2/3 programme in over 500 women, which is the study that will actually determine whether VDPHL01 gets approved for female pattern hair loss. Topline results are anticipated in the first half of 2027. Until then, the female data is a genuinely positive early signal, not evidence of the same weight as the male Study '302' results.
What's Still Pending
Two further pivotal programmes are still underway. Study '304' is the confirmatory Phase 3 trial for the male indication. Veradermics' press materials describe 536 men, while ClinicalTrials.gov lists an estimated enrollment of 480. The discrepancy isn't explained in the public materials, so we report both figures rather than choosing between them. Enrollment completed in February 2026 and topline results are expected in the second half of 2026, which as of writing haven't been reported yet. Study '306' is the separate Phase 2/3 programme in women, still enrolling, with topline data anticipated in the first half of 2027. Study '302' also has a longer-term Part B dataset, covering 12 months of treatment rather than the 6-month topline results above, also due in the second half of 2026, which should provide useful information on longer-term efficacy and durability for a drug intended for chronic, ongoing use.
Veradermics has stated that its current cash position is sufficient to fund operations through multiple Phase 3 readouts and a potential launch, following an IPO and follow-on financing in 2026. As of writing, VDPHL01 is not approved anywhere and not available for purchase through any legitimate channel.
Two Different Companies Both Claiming "First in 30 Years"
Worth noticing directly: Veradermics describes VDPHL01 as positioned to become "the first FDA-approved oral pill in nearly 30 years for pattern hair loss." Cosmo Pharmaceuticals uses almost identical language for Breezula, "the first potential innovation in over 30 years in male hair loss." Both companies are reaching for the same 30-year marker, finasteride's 1997 approval, and both claims are referring to a different kind of "first."
Breezula's active molecule, clascoterone, is genuinely new to AGA treatment: a different mechanism entirely, a topical androgen receptor antagonist rather than a systemic 5-alpha reductase inhibitor or a growth-cycle modulator, as covered in our separate article on that drug. VDPHL01's active molecule is minoxidil, already approved and in use since 1988; what's new is the delivery formulation and the oral route being formally developed and tested for this specific indication, rather than a new mechanism of action. Both are legitimate "firsts," just firsts of different things: one a new drug class reaching approval, the other a new formulation of an existing drug finally being properly developed rather than used off-label. Worth keeping that distinction in mind when either company's marketing language shows up in coverage of either drug.
Where This Leaves Today's Off-Label Oral Minoxidil
VDPHL01's existence doesn't make today's off-label, immediate-release oral minoxidil prescribing wrong or obsolete; the international consensus statement and safety data covered in our oral vs topical minoxidil article still applies to the drug currently being prescribed. What VDPHL01 represents is a possible future upgrade path: a version of the same active molecule specifically engineered and formally tested to reduce the peak-concentration-related systemic effects that can limit the current off-label approach. Whether it delivers on that in practice, at scale, and whether regulators agree the evidence is sufficient, remains an open question. Study '304' is the key next test for the male indication, while Study '306' will determine whether the approach can support a female indication.
Frequently Asked Questions
Is VDPHL01 just minoxidil in a new bottle?
The active ingredient is the same molecule as existing oral and topical minoxidil. What's different is the extended-release delivery technology, designed to change how that molecule is released into the bloodstream over time, aiming for a flatter, more sustained concentration rather than the sharp peak and decline typical of an immediate-release tablet.
Is the female data as strong as the male data?
Not yet, and it isn't meant to be at this stage. The available female data comes from a small, open-label Phase 2 study without a placebo comparator, run specifically as proof-of-concept ahead of the placebo-controlled Phase 2/3 trial that will actually support a female approval decision. The male data comes from a much larger, randomised, placebo-controlled trial, which is a meaningfully stronger form of evidence.
When might VDPHL01 be available?
Not before the confirmatory male programme reports and Veradermics submits an application, followed by regulatory review. Female approval would follow the separate Study '306' readout, anticipated in the first half of 2027, and its own subsequent review. There's no confirmed launch date, and timelines at this stage of drug development commonly move.
Does this mean current oral minoxidil prescribing is outdated?
No. Immediate-release oral minoxidil has a real, if still developing, safety and consensus evidence base behind current off-label use, covered in our other article on the subject. VDPHL01 is a potential future alternative aimed at a specific limitation of that approach, not a signal that the current one is unsafe or shouldn't be used.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. VDPHL01 is an investigational drug not approved by any regulator and not available for purchase through any legitimate channel. AmpleLab products are cosmetic formulations, unrelated to VDPHL01, and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.